Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Browse By Topic
Personalized Medicine
Personalized Medicine
Articles about personalized medicine on Value-Based Cancer Care. Learn how to utilize a patient's unique genetic makeup and environment to customize the patient's medical care and treatment.
Filter by Topic
Cancer Care
Cancer Drugs
Cancer Prevention
Cancer Quick Takes
Cancer Rehabilitation
Cancer Screening
Cervical Cancer
Chemotherapy
Clinical Research
Clinical Trials
Emerging Therapies
Genetic Testing
Hematologic Malignancies
Hormone Therapy
Immunotherapy
Multidisciplinary Care
Palliative Care
Pregnancy & Cancer
Prognostic Tests
Radiation Therapy
Radiotherapy in Focus
Sentinel Node Management
Solid Tumors
Urine Biopsies Detect Early Mutations in Patients with Advanced Cancers
By
Wayne Kuznar
Personalized Medicine
December 2015, Vol 6, No 11
An assay that measures circulating tumor (ct) DNA in the urine can detect mutations in patients with a variety of advanced cancers, according to a recent study.
Read Article
Personalized Medicine a Vital Aspect of Palliative Care
By
Meg Barbor, MPH
Palliative Care
,
Personalized Medicine
December 2015, Vol 6, No 11
Boston, MA—Delivering the keynote lecture at the 2015 Palliative Care in Oncology Symposium, Howard L. McLeod, PharmD, Medical Director of the DeBartolo Family Personalized Medicine Institute at Moffitt Cancer Center, Tampa, FL, discussed advances in personalized medicine as they relate to palliative care, as well as the continuing challenges in cancer care.
Read Article
Genomic Test Supports Treatment Decisions in Prostate Cancer
By
Phoebe Starr
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
December 2015, Vol 6, No 11
San Antonio, TX—A genomic classifier is now available that can predict a low or high risk for metastasis in men with prostate cancer who have rising prostate-specific antigen (PSA) after a prostatectomy. The good news is that this test is reimbursable by Medicare.
Read Article
80-Gene Assay Identifies Distinct Triple-Positive Breast Cancer Subtypes, Guides Therapy Selection
By
Corbin Davis
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
November 2015, Vol 6, No 10
San Francisco, CA—A new genetic test may allow clinicians to improve their therapy decisions by better categorizing patients into specific subtypes compared with conventional immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) subtyping. According to data presented at the 2015 Breast Cancer Symposium, the BluePrint 80-gene assay reclassifies approximately 23% of tumors, allowing for more effective therapy selection, particularly in patients with triple-positive (HER2-positive/hormone receptor–positive) disease.
Read Article
Chemotherapy Safe During Pregnancy in Second and Third Trimesters
By
Phoebe Starr
Chemotherapy
,
Pregnancy & Cancer
,
Personalized Medicine
November 2015, Vol 6, No 10
Vienna, Austria—Results from a new study provide reassurance to women who have cancer while pregnant that they can safely receive treatment during the second or third trimester with chemotherapy or radiation without compromising their unborn child. The study showed that children born to mothers who receive chemotherapy or radiation during pregnancy had no impairment in general health, cognition, or cardiac function compared with children born to healthy mothers, said lead investigator Frédéric Amant, MD, PhD, Department of Gynecologic Oncology, University Hospitals Leuven, Belgium.
Read Article
Screening in Younger First-Degree Relatives of Patients with CRC
By
Rosemary Frei, MSc
Cancer Screening
,
Personalized Medicine
November 2015, Vol 6, No 10
A study from the Centers for Disease Control and Prevention documented an average 38% colorectal cancer (CRC) screening rate among people aged 40 to 49 years, and a 69.7% rate in those aged ?50 years with a first-degree relative with CRC. An earlier analysis of National Health Interview Survey (NHIS) data from 2005 and 2010 showed that first-degree relatives of patients with CRC were 70% more likely to have a colonoscopy than their counterparts.
Read Article
MRI Screening of Women at Average Risk for Breast Cancer Improves Detection
By
Corbin Davis
Breast Cancer
,
Cancer Screening
,
Personalized Medicine
November 2015, Vol 6, No 10
San Francisco, CA—Magnetic resonance imaging (MRI) screening of women who are at average risk for breast cancer had a mean additional cancer diagnosis yield of 15.8 per 1000 patients, surpassing the yields for digital breast tomosynthesis and ultrasound in a new study. The results were presented at the 2015 Breast Cancer Symposium, by Christiane K. Kuhl, MD, Department of Diagnostic and Interventional Radiology, RWTH Aachen University, Germany. This suggests that breast MRI screening alone every 3 years may be sufficient for women at average risk.
Read Article
Significant Benefits Seen with 2 New Options for Patients with Renal-Cell Carcinoma
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
November 2015, Vol 6, No 10
Vienna, Austria—Patients with advanced, pretreated renal-cell carcinoma (RCC) who have limited treatment options got good news from 2 important practice-changing trials, CheckMate 025 and METEOR, which were presented as late-breaking abstracts at the 2015 European Cancer Congress (ECC). CheckMate 025 showed a survival benefit for nivolumab (Opdivo) over standard therapy with everolimus (Afinitor) in patients with previously treated advanced RCC. This is the first trial to show a survival benefit for an immune checkpoint inhibitor after standard therapy has failed. METEOR showed that cabozantinib (Cometriq) nearly doubled progression-free survival (PFS) compared with standard everolimus in patients with advanced RCC whose disease progressed with previous vascular endothelial growth factor (VEGF) receptor (VEGFR)-targeted therapy.
Read Article
Everolimus, 177Lu-DOTATATE Potentially 2 Practice-Changing Options in NETs
By
Phoebe Starr
Emerging Therapies
,
Personalized Medicine
November 2015, Vol 6, No 10
“Everolimus is the first targeted agent to show robust antitumor activity with acceptable tolerability across a broad spectrum of NETs,” said James C. Yao, MD.
Read Article
Using Genetics to Guide Pembrolizumab Therapy in CRC
By
Dana Taylor
Emerging Therapies
,
Personalized Medicine
October 2015, Vol 6, No 9
The treatment of patients with colorectal cancer (CRC) may benefit from immunotherapy with anti–PD-1 agents, based on results of a recent study using pembrolizumab (Keytruda).
Read Article
Page 17 of 35
14
15
16
17
18
19
20
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
Talvey Receives Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma